MytoLyfe Biotherapeutics
Improving the lives of those with mitochondrial diseases
MytoLyfe Biotherapeutics
Improving the lives of those with mitochondrial diseases
Our Mission/ Our Passion
MytoLyfe Biotherapeutics targets mitochondrial dysfunction to manage symptoms and slow disease progression for patients with mitochondrial disorders. Our passion is to develop small molecule therapeutics that stimulate mitochondrial biogenesis.
MytoLyfe Biotherapeutics passion is to develop small molecule therapeutics that stimulate mitochondrial biogenesis.
Consider This:
- 1 in 5,000 people worldwide are affected by a mitochondrial disease.
- Most affect the CNS.
- Every 30 minutes, a child is born who will develop a mitochondrial disorder by age 10.
- It is the second most commonly diagnosed serious genetic disorder after cystic fibrosis.
Leigh is the Most Common Pediatric Mitochondrial Disease
- There is no approved therapy globally. Patients are largely reliant on nutritional supplements, physical therapy and some conventional epileptic drugs.
- By increasing mitochondrial activity, the severity of symptoms may be alleviated such as swallowing, motor function and speech.
- $1B peak orphan sales potential at supportable orphan drug pricing and unlimited peak sales potential in overall application for drug pricing.
Meet the MytoLyfe Team
J Todd Derbin
CHAIRMAN AND
CHIEF EXECUTIVE OFFICER
Co-Founder, Chairman and CEO. With over 35 years of broad global senior executive tenure spanning all aspects of life sciences, Todd has been instrumental in founding and building leading edge organizations in biotechnology and medical devices. He has taken four companies from the startup phase to successful exits totaling in excess of $2.5B.
Janice Keramedjian
CHIEF MARKETING OFFICER
Co-Founder and Chief Marketing Officer. With 30 years successful serial entrepreneur in strategic planning, Janice brings C-Suite Directorship skills in integrative marketing and communications. She is a Top Tier industry advisor and spokesperson for Patient Advocacy Groups
Beverly W. Lubit, JD, Ph.D.
PATENT COUNSEL
Dr. Lubit has decades of experience- as IP counsel, scientific, regulatory compliance, and deal advisor- successfully guiding clients to realizing the potential of their technologies, products and services to improve lives. She has a broad hands-on technical knowledge of the applications driving innovation and has secured dozens of patents relating to a vast number of different treatments and technologies. From cutting-edge cancer, stem cell and neurochemistry to orthopedic devices, dietary supplements and more, her practice has touched an extraordinarily wide array of groundbreaking work.
Robert McFarland, MA MBBS Ph.D. MRCP FRCPCH
SAB ADVISOR
Professor of Paediatric Mitochondrial Medicine
Action Medical Research Professor of Neuromuscular Disease Honorary Consultant Paediatric Neurologist
Director Highly Specialised Service for Rare Mitochondrial Disorders of Adults and Children
Wellcome Centre for Mitochondrial Research
Translational and Clinical Research Institute
Faculty of Medical Sciences
Newcastle University
Mark Olsen, Ph.D.
SAB ADVISOR
Associate Professor, Midwestern University, Glendale AZ; Medicinal Chemist; Antiepileptogenic Agents, Inhibition of 2-oxoglutarate utilizing enzymes, Aspartyl-beta-hydroxylase inhibitors for anticancer treatment
Madhu Davies, MB ChB
SAB ADVISOR
Clinical development, drug safety and pharmacovigilence professional with over 20 years of experience. Roles have included Chief Medical Officer, corporate Medical Director and Non-Executive Director.
We Support the Mission of Wellcome Centre for Mitochondrial Research
We Support the Mission of United Mitochondrial Disease Foundation
We Support the Mission of Cure Mito Foundation
We Support the Mission of MitoWorld
We Support the Mission of MitoAction
Contact US
MytoLyfe Biotherapeutics Ltd.
17 Marble Street, Manchester, M2 3AW, United Kingdom
